553 related articles for article (PubMed ID: 9823304)
21. Genetic deletions in sputum as diagnostic markers for early detection of stage I non-small cell lung cancer.
Li R; Todd NW; Qiu Q; Fan T; Zhao RY; Rodgers WH; Fang HB; Katz RL; Stass SA; Jiang F
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):482-7. PubMed ID: 17255269
[TBL] [Abstract][Full Text] [Related]
22. Altered expression of Fhit in carcinoma and precarcinomatous lesions of the esophagus.
Mori M; Mimori K; Shiraishi T; Alder H; Inoue H; Tanaka Y; Sugimachi K; Huebner K; Croce CM
Cancer Res; 2000 Mar; 60(5):1177-82. PubMed ID: 10728669
[TBL] [Abstract][Full Text] [Related]
23. Fragile histidine triad expression in oral squamous cell carcinoma and precursor lesions.
Kujan O; Oliver R; Roz L; Sozzi G; Ribeiro N; Woodwards R; Thakker N; Sloan P
Clin Cancer Res; 2006 Nov; 12(22):6723-9. PubMed ID: 17121892
[TBL] [Abstract][Full Text] [Related]
24. Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions.
Hao XP; Willis JE; Pretlow TG; Rao JS; MacLennan GT; Talbot IC; Pretlow TP
Cancer Res; 2000 Jan; 60(1):18-21. PubMed ID: 10646844
[TBL] [Abstract][Full Text] [Related]
25. FHITness and cancer.
Druck T; Berk L; Huebner K
Oncol Res; 1998; 10(7):341-5. PubMed ID: 10063967
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological significance of the fragile histidine triad transcription protein expression in laryngeal carcinogenesis.
Kitamura K; Hayashi K; Kobayashi R; Ishii H; Matsubayashi J; Matsumoto T; Suzuki M
Oncol Rep; 2008 Apr; 19(4):847-52. PubMed ID: 18357366
[TBL] [Abstract][Full Text] [Related]
27. Molecular analysis of the FHIT gene at 3p14.2 in lung cancer cell lines.
Yanagisawa K; Kondo M; Osada H; Uchida K; Takagi K; Masuda A; Takahashi T; Takahashi T
Cancer Res; 1996 Dec; 56(24):5579-82. PubMed ID: 8971157
[TBL] [Abstract][Full Text] [Related]
28. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer.
Kim H; Kwon YM; Kim JS; Lee H; Park JH; Shim YM; Han J; Park J; Kim DH
J Clin Oncol; 2004 Jun; 22(12):2363-70. PubMed ID: 15197197
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of p16INK4A inactivation in non small-cell lung cancers.
Gazzeri S; Gouyer V; Vour'ch C; Brambilla C; Brambilla E
Oncogene; 1998 Jan; 16(4):497-504. PubMed ID: 9484839
[TBL] [Abstract][Full Text] [Related]
30. The expression of Fhit protein is related inversely to disease progression in patients with breast carcinoma.
Gatalica Z; Lele SM; Rampy BA; Norris BA
Cancer; 2000 Mar; 88(6):1378-83. PubMed ID: 10717620
[TBL] [Abstract][Full Text] [Related]
31. 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer.
Zöchbauer-Müller S; Fong KM; Maitra A; Lam S; Geradts J; Ashfaq R; Virmani AK; Milchgrub S; Gazdar AF; Minna JD
Cancer Res; 2001 May; 61(9):3581-5. PubMed ID: 11325823
[TBL] [Abstract][Full Text] [Related]
32. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
[TBL] [Abstract][Full Text] [Related]
33. Aberrations in the fragile histidine triad (FHIT) gene in idiopathic pulmonary fibrosis.
Uematsu K; Yoshimura A; Gemma A; Mochimaru H; Hosoya Y; Kunugi S; Matsuda K; Seike M; Kurimoto F; Takenaka K; Koizumi K; Fukuda Y; Tanaka S; Chin K; Jablons DM; Kudoh S
Cancer Res; 2001 Dec; 61(23):8527-33. PubMed ID: 11731438
[TBL] [Abstract][Full Text] [Related]
34. Reduced Fhit protein expression and loss of heterozygosity at FHIT gene in tumours from smoking and asbestos-exposed lung cancer patients.
Pylkkanen L; Wolff H; Stjernvall T; Tuominen P; Sioris T; Karjalainen A; Anttila S; Husgafvel-Pursiainen K
Int J Oncol; 2002 Feb; 20(2):285-90. PubMed ID: 11788890
[TBL] [Abstract][Full Text] [Related]
35. Expression of PTEN and FHIT is involved in regulating the balance between apoptosis and proliferation in lung carcinomas.
Zheng H; Tsuneyama K; Takahashi H; Miwa S; Nomoto K; Saito H; Masuda S; Takano Y
Anticancer Res; 2007; 27(1B):575-81. PubMed ID: 17348444
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological significance of aberrant methylation of RARbeta2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancer.
Tomizawa Y; Iijima H; Nomoto T; Iwasaki Y; Otani Y; Tsuchiya S; Saito R; Dobashi K; Nakajima T; Mori M
Lung Cancer; 2004 Dec; 46(3):305-12. PubMed ID: 15541815
[TBL] [Abstract][Full Text] [Related]
37. The Fragile Histidine Triad gene and breast cancer.
Yang Q; Yoshimura G; Sakurai T; Kakudo K
Med Sci Monit; 2002 Jul; 8(7):RA140-4. PubMed ID: 12118213
[TBL] [Abstract][Full Text] [Related]
38. Decreased fragile histidine triad gene messenger RNA expression in lung cancer.
Sasaki H; Haneda H; Yukiue H; Kobayashi Y; Yano M; Fujii Y
Clin Lung Cancer; 2006 May; 7(6):412-6. PubMed ID: 16800968
[TBL] [Abstract][Full Text] [Related]
39. Role of FHIT in human cancer.
Croce CM; Sozzi G; Huebner K
J Clin Oncol; 1999 May; 17(5):1618-24. PubMed ID: 10334551
[TBL] [Abstract][Full Text] [Related]
40. Frequent abnormalities of FHIT, a candidate tumor suppressor gene, in head and neck cancer cell lines.
Mao L; Fan YH; Lotan R; Hong WK
Cancer Res; 1996 Nov; 56(22):5128-31. PubMed ID: 8912845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
